4.5 Article Proceedings Paper

Cardiovascular autonomic dysfunction in Parkinson's disease

期刊

JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 289, 期 1-2, 页码 74-80

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2009.08.031

关键词

Parkinson's disease; Cardiovascular dysautonomia; Orthostatic hypotension

向作者/读者索取更多资源

Symptoms of cardiovascular dysautonomia are a common occurrence in Parkinson's disease (PD) In addition to this dysautonomia as part of PD itself, dysfunction of the autonomic nervous system (ANS) can be triggered as a side-effect of drug treatment interacting with the ANS or - if prominent and early - an indication of a different disease such as multiple system atrophy (MSA) Various diagnostic tests are available to demonstrate autonomic failure While autonomic function tests can differentiate parasympathetic from sympathetic dysfunction, cardiac imaging can define the pathophysiologically involved site of a lesion Standard tests such as 24-h ambulatory blood pressure measurements can identify significant autonomic failure which needs treatment The most frequent and disturbing symptom of cardiovascular autonomic dysfunction is orthostatic hypotension Symptoms include generalized weakness. light-headiness, mental clouding Lip to syncope Factors like heat, food, alcohol, exercise, activities which increase intrathoraric pressure (eg defecation, coughing) and certain drugs (eg vasodilators) can worsen a probably asymptomatic orthostatic hypotension Non-medical and medical therapies can help the patient to cope with a disabling symptomatic orthostatic hypotension. Supine hypertension is often associated with orthostatic hypotension The prognostic role of cardiovagal and baroreflex dysfunction is still not yet known (C) 2009 Elsevier B.V All rights reserved

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Medicine, General & Internal

MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression

Tjalf Ziemssen, Jo Vandercappellen, Valeria Jordan Mondragon, Gavin Giovannoni

Summary: This article introduces the development and benefits of the MSProDiscuss clinical decision support tool for neurologists to improve care for MS patients. MS is a progressive disease with heterogeneous symptoms, and early intervention is crucial. MSProDiscuss facilitates structured patient consultations, analyzes multidimensional data, and provides personalized treatment and disease management plans.

JOURNAL OF CLINICAL MEDICINE (2022)

Review Clinical Neurology

Secondary Progressive Multiple Sclerosis A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies

Tjalf Ziemssen, Virender Bhan, Jeremy Chataway, Tanuja Chitnis, Bruce Anthony Campbell Cree, Eva Kubala Havrdova, Ludwig Kappos, Pierre Labauge, Aaron Miller, Jin Nakahara, Celia Oreja-Guevara, Jacqueline Palace, Barry Singer, Maria Trojano, Ashwini Patil, Benedict Rauser, Thomas Hach

Summary: There are many challenges in accurately diagnosing and managing SPMS due to the lack of definitive criteria for the transition from RRMS to SPMS. This review discusses the diagnostic criteria/definition and the heterogeneity of SPMS patient populations, and emphasizes the importance of early identification through prospective/retrospective tools to improve outcomes with approved treatments. Effective interventions require ongoing patient-clinician dialogue within a multidisciplinary team.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Clinical Neurology

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies

Colin M. Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F. Hunter, Krzysztof W. Selmaj, Hans-Peter Hartung, Eva K. Havrdova, Christopher C. LaGanke, Tjalf Ziemssen, Bart Van Wijmeersch, Sven G. Meuth, David H. Margolin, Elizabeth M. Poole, Darren P. Baker, Peter A. Senior

Summary: This study aimed to describe the endocrine and multiple sclerosis outcomes over 6 years for alemtuzumab-treated relapsing multiple sclerosis patients. The results showed that the common adverse event of this treatment was autoimmune thyroid events, but it did not affect the disease course.

MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL (2023)

Article Clinical Neurology

Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis

Tammy Jiang, Tjalf Ziemssen, Sibyl Wray, Changyu Shen, Karin Soderbarg, James B. Lewin, Ivan Bozin, Mark S. Freedman

Summary: This study compared the differences between Diroximel fumarate (DRF) and ponesimod (PON) as well as DRF and teriflunomide (TERI) in terms of clinical and radiological outcomes. The study found that there was no strong evidence of differences between DRF and PON in the treatment of relapsing multiple sclerosis, but DRF showed improved efficacy compared to TERI.

CNS DRUGS (2023)

Article Medicine, General & Internal

Data Resource Profile: The Multiple Sclerosis Documentation System 3D and AOK PLUS Linked Database (MSDS-AOK PLUS)

Marco Ghiani, Evi Zhuleku, Anja Dillenseger, Ulf Maywald, Andreas Fuchs, Thomas Wilke, Tjalf Ziemssen

Summary: This study introduces a novel database that links administrative claims and medical records, allowing for a complete capture of patient profiles. Currently including 500 patients, this database has the potential to enhance the quality and scope of real-world studies in multiple sclerosis.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Immunology

Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis

Tjalf Ziemssen, Eugen Schlegel, Marie Groth, Benjamin Ettle, Tobias Bopp

Summary: Booster vaccinations increase neutralizing antibody titers in ofatumumab-treated patients. A booster is recommended in ofatumumab-treated patients.

VACCINES (2023)

Article Biochemistry & Molecular Biology

Countermovement Jumps Detect Subtle Motor Deficits in People with Multiple Sclerosis below the Clinical Threshold

Anne Gessner, Heidi Stoelzer-Hutsch, Katrin Trentzsch, Dirk Schriefer, Tjalf Ziemssen

Summary: In the early stages of multiple sclerosis (MS), there are currently no sensitive assessments to evaluate complex motor functions. The countermovement jump (CMJ) has been investigated as a reliable assessment for lower extremity motor function in healthy subjects. This study aimed to determine if CMJ could identify motor deficits in individuals with MS below the clinical threshold. The results showed that individuals with MS demonstrated significantly decreased CMJ performance compared to healthy controls, indicating that CMJ could detect motor deficits in MS patients.

BIOMEDICINES (2023)

Article Biochemistry & Molecular Biology

Influence of Pre-Analytic Conditions on Quantity of Lymphocytes

Undine Proschmann, Puya Shalchi Amirkhiz, Pauline Andres, Rocco Haase, Hernan Inojosa, Tjalf Ziemssen, Katja Akgun

Summary: This study aims to evaluate the impact of various pre-analytic conditions on immune cell counts and draw conclusions for clinical implications. The results suggest that storage temperature significantly affects immune cell counts, while tourniquet application duration, body position, and aspiration speed during blood draws do not have significant impacts. Pre-analytic conditions should be carefully considered when interpreting laboratory values of immune cell subpopulations.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Clinical Neurology

Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination

Undine Proschmann, Magdalena Mueller-Enz, Christina Woopen, Georges Katoul Al Rahbani, Rocco Haase, Anja Dillenseger, Marie Dunsche, Yassin Atta, Tjalf Ziemssen, Katja Akguen

Summary: The study found differential effects of selective versus unselective S1PRMs on the immune response to SARS-CoV-2 vaccination, with patients on selective S1PRMs exhibiting lower antibody levels and diminished T-cell response.

MULTIPLE SCLEROSIS JOURNAL (2023)

Article Immunology

Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod-Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)

Tjalf Ziemssen, Marie Groth, Veronika Eva Winkelmann, Tobias Bopp

Summary: This study examines the effect of SARS-CoV-2 mRNA vaccination in patients receiving siponimod treatment. The results demonstrate favorable antibody and T-cell responses in patients at six months and after the booster dose.

VACCINES (2023)

Article Immunology

Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy

Christina Woopen, Marie Dunsche, Georges Katoul Al Rahbani, Anja Dillenseger, Yassin Atta, Rocco Haase, Catarina Raposo, Rosetta Pedotti, Tjalf Ziemssen, Katja Akgun

Summary: The objective of this study was to compare cellular and humoral immune responses to SARS-CoV-2 vaccination between multiple sclerosis (pwMS) patients on B-cell depleting treatment (BCDT) and those without immunotherapy. The results showed that BCDT patients had lower humoral responses but higher cellular responses. The immune responses decreased over time after primary vaccination and increased again after booster vaccination. Untreated and B-cell-depleted pwMS patients had higher antibody titers after booster vaccination. COVID-19 infection led to a significant increase in SARS-CoV-2-specific responses. A third vaccination for BCDT patients is recommended, and assessing T-cell responses may be helpful in evaluating the efficacy of SARS-CoV-2 vaccination.

VACCINES (2023)

Letter Clinical Neurology

Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication

Hernan Inojosa, Stephen Gilbert, Jakob Nikolas Kather, Undine Proschmann, Katja Akgun, Tjalf Ziemssen

NEUROLOGICAL RESEARCH AND PRACTICE (2023)

Article Behavioral Sciences

The chronic stress risk phenotype mirrored in the human retina as a neurodegenerative condition

Leone Malan, Roelof van Wyk, Roland von Kanel, Tjalf Ziemssen, Walthard Vilser, Peter M. Nilsson, Martin Magnusson, Amra Jujic, Daniel W. Mak, Faans Steyn, Nico T. Malan

Summary: The brain is the key organ that orchestrates the stress response which translates to the retina. The retina is an extension of the brain and retinal symptoms in subjects with neurodegenerative diseases substantiated the eye as a window to the brain. The retina is used in this study to determine whether chronic stress reflects neurodegenerative signs indicative of neurodegenerative conditions.

STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS (2023)

Article Health Care Sciences & Services

Correlation and differences of patient-reported outcomes vs. Likert-Rating of MS symptoms in a real-world cohort using a digital patient app

Steffeni Mountford, Maria Kahn, Preetha Balakrishnan, Elizabeth Jacyshyn-Owen, Markus Eberl, Benjamin Friedrich, Natalie Joschko, Tjalf Ziemssen

Summary: BRISA is a digital app designed to help MS patients monitor their disease by tracking symptoms. Simplified versions of questionnaires can provide comparable information regarding individual symptom presentations. However, traditional questionnaires are still needed for a more objective assessment.

DIGITAL HEALTH (2023)

Article Clinical Neurology

Safety and efficacy with alemtuzumab over 13?years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Alasdair J. Coles, Anat Achiron, Anthony Traboulsee, Barry A. Singer, Carlo Pozzilli, Celia Oreja-Guevara, Gavin Giovannoni, Giancarlo Comi, Mark S. Freedman, Tjalf Ziemssen, Debora Shiota, Andreea M. Rawlings, Alana T. Wong, Magdalena Chirieac, Xavier Montalban

Summary: The safety risks associated with alemtuzumab treatment decreased over time, and the clinical benefits were maintained for 11-13 years, with most patients not requiring additional courses.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

暂无数据